Jianmin Pharmaceutical Group (600976) Fundamentals 2026 — P/E 13.2x, Revenue Analysis | SniperIQ
Jianmin Pharmaceutical Group (600976) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.5B, trading at ¥29.08 on the SHH. This SniperIQ fundamentals page covers Jianmin Pharmaceutical Group's valuation (P/E 13.2x, P/B 1.6x), profitability (net margin 10.1%), revenue (¥3.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jianmin Pharmaceutical Group's market cap?
Jianmin Pharmaceutical Group (600976) has a market capitalization of approximately ¥4.5B, trading at ¥29.08 on the SHH. Market cap moves with the live share price.
What is Jianmin Pharmaceutical Group's P/E ratio?
Jianmin Pharmaceutical Group's trailing twelve-month P/E ratio is 13.2x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jianmin Pharmaceutical Group?
Jianmin Pharmaceutical Group runs a net profit margin of 10.1%, a gross margin of 60.0%, and an operating margin of 5.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jianmin Pharmaceutical Group generate?
Jianmin Pharmaceutical Group reported revenue of ¥3.4B for fiscal year 2025, with net income of ¥360M and earnings per share (EPS) of 2.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jianmin Pharmaceutical Group pay a dividend?
Jianmin Pharmaceutical Group offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jianmin Pharmaceutical Group financially healthy?
Jianmin Pharmaceutical Group carries a debt-to-equity ratio of 0.09x and a current ratio of 1.55x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jianmin Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jianmin Pharmaceutical Group (600976) the key facts are: market cap ¥4.5B, P/E 13.2x, revenue ¥3.4B, 52-week range 24.68-43.72. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jianmin Pharmaceutical Group's full fundamentals live
Get Jianmin Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.